Extracorporeal cytokine adsorption as an alternative to pharmacological inhibition of IL-6 in COVID-19
- PMID: 32819415
- PMCID: PMC7439244
- DOI: 10.1186/s13054-020-03238-1
Extracorporeal cytokine adsorption as an alternative to pharmacological inhibition of IL-6 in COVID-19
Conflict of interest statement
Alexander Supady and D Duerschmied received speakers’ honoraria from CytoSorbents, the manufacturer of the CytoSorb® device. The Department of Cardiology and Angiology I received a research grant from CytoSorbents.
Comment on
-
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients.Crit Care. 2020 Jun 11;24(1):331. doi: 10.1186/s13054-020-03020-3. Crit Care. 2020. PMID: 32527304 Free PMC article.
References
-
- Convertino I, Tuccori M, Ferraro S, Valdiserra G, Cappello E, Focosi D, Blandizzi C. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Crit Care. 2020;24(1):331. doi: 10.1186/s13054-020-03020-3. - DOI - PMC - PubMed
-
- Sinha P, Matthay MA, Calfee CS: Is a “Cytokine Storm” relevant to COVID-19? JAMA Intern Med. 2020. 10.1001/jamainternmed.2020.3313. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources